| Target Molecule | Angiotensin II (1-4) (human) |
| Synonyms | Ang II (1-4); Angiotensin (1-4); DRVY; H-Asp-Arg-Val-Tyr-OH; Angiotensinogen (34-37) |
| CAS Number | 52580-29-7 |
| Sequence (3-Letter) | H-Asp-Arg-Val-Tyr-OH |
| Sequence (1-Letter) | DRVY |
| Molecular Formula | C₂₄H₃₇N₇O₈ |
| Molecular Weight | 551.6 |
| Service Category | Custom Peptide Synthesis / CDMO Manufacturing |
| Synthesis Purity | Customizable (e.g., ≥95%, ≥98% via HPLC) |
| Appearance | White to off-white lyophilized powder |
| Counter Ion | Trifluoroacetate (TFA), acetate, or custom salt options |
| Synthesis Technology | Solid-Phase Peptide Synthesis (SPPS) and Liquid-Phase Synthesis |
| Modification Options | Stable isotope labeling (13C, 15N), fluorescent/biotin tagging, terminal modifications |
| Available Scale | Milligram (R&D) to Kilogram (Commercial CDMO) |
| Analytical Data | Comprehensive COA, HPLC, MS, and extended documentation provided per batch |
| Usage | Raw material synthesized strictly for laboratory research, analytical development, and industrial formulation. Not a finished medicine. |
Angiotensin II (1-4) (CAS 52580-29-7) is the N-terminal tetrapeptide metabolite (DRVY) of angiotensin II. We target this sequence to supply high-purity reference materials, analytical calibration markers, and raw materials for cardiovascular and metabolic research.
We utilize optimized solid-phase peptide synthesis (SPPS) and solution-phase methodologies. Our peptide synthesis platform ensures complete coupling efficiency and strict chromatographic purification, eliminating deletion fragments and delivering reproducible, high-purity reference standards.
Yes. We provide specialized peptide modification services for the DRVY sequence. Capabilities include site-specific stable isotope labeling (such as 13C and 15N) for quantitative mass spectrometry (LC-MS/MS), N-terminal acylation, and fluorescent or biotin tags for enzymatic tracking.
Our manufacturing infrastructure scales seamlessly from milligram-level analytical batches to multi-gram and kilogram commercial production. We utilize high-capacity preparative HPLC and robust lyophilization processes to maintain strict lot-to-lot consistency.
We operate as a technical partner providing complete peptide CDMO solutions. Our team manages sequence optimization, impurity profiling, analytical method validation, and regulatory documentation to support complex drug development and biomarker quantification pipelines.
Angiotensin II (1-4), defined by the tetrapeptide sequence DRVY (H-Asp-Arg-Val-Tyr-OH), is a major enzymatic breakdown product of angiotensin II within the renin-angiotensin system (RAS). Synpeptide delivers comprehensive custom synthesis solutions for this target molecule, providing analytical-grade reference standards and raw materials for pharmacokinetic profiling, metabolic mapping, and assay development.
Synthesizing short, hydrophilic peptide sequences requires specialized handling to avoid coupling inefficiencies and purification loss. Our custom peptide synthesis platform utilizes optimized Solid-Phase Peptide Synthesis (SPPS) and liquid-phase chemistry protocols. By employing high-efficiency coupling reagents and precise cleavage controls, we suppress deletion byproducts and isolate Angiotensin II (1-4) at high purity levels (typically ≥95% or ≥98% via HPLC) for rigorous analytical calibration.
Quantitative liquid chromatography-tandem mass spectrometry (LC-MS/MS) of biological fluids often encounters matrix effects that necessitate exact internal standards. Through our peptide modification services, we synthesize stable-isotope-labeled Angiotensin II (1-4) incorporating heavy amino acids (such as uniformly labeled 13C and 15N Val or Tyr). We also provide terminal modifications, fluorescent labels, and biotin conjugates to facilitate enzymatic cleavage assays and biomarker validation.
When reference standards or pathway metabolites are required across broad analytical screening programs, supply consistency is essential. We execute large-scale peptide synthesis for Angiotensin II (1-4) and related RAS cascade peptides. Our scalable preparative HPLC infrastructure and controlled lyophilization protocols support production from milligram research batches to kilogram commercial quantities, ensuring identical counter-ion profiles and impurity thresholds across all lots.
We provide full structural verification and analytical documentation as an integrated peptide CDMO. Our technical specialists assist pharmaceutical and clinical laboratories with analytical method validation, counter-ion exchange (including TFA removal to acetate), and comprehensive stability profiling. We supply fully characterized materials accompanied by complete COA, MS, and HPLC documentation to accelerate preclinical research workflows.
